（2027年4月28日，中国上海）4月27日，复星医药（600196.SH；02196.HK）与总部位于阿联酋阿布扎比的全球性生命科学公司Arcera Life Sciences LLC OPC（以下简称“Arcera”）签署合作备忘录，双方将聚焦全球生命科学领域的授权许可、技术开发、神经科学领域创新及价值创造，建立长期战略合作关系。
复星医药联席总裁、创新药事业部首席执行官王兴利与Arcera首席投资官Sunil Bhilotra在上海签署协议；复星国际联席董事长汪群斌、复星医药董事长陈玉卿、Arcera首席执行官Isabel Afonso、Arcera企业发展高级副总裁Rafael Ferrer现场见证签约。
本次合作契合中阿全面战略伙伴关系与阿布扎比医疗健康与生命科学2030愿景，旨在将复星医药全球化的创新研发及生产制造能力与Arcera国际市场准入及商业化体系结合，双方优势互补、合作共赢，还致力于将阿布扎比打造为中国生物技术创新对接全球市场的核心枢纽，加速推动创新突破性疗法惠及中东及全球患者。
根据合作备忘录，双方将在多个领域开展战略合作：
1
区域与全球市场许可合作方面，双方将评估及推动复星医药在中国已上市或处于临床后期的创新产品在中东及全球市场的授权与商业化，潜在合作项目涵盖肿瘤、神经退行性疾病、罕见病及心血管代谢等领域。
2
前沿技术孵化方面，双方未来将探索在阿布扎比建立合资公司或NewCo公司，聚焦小分子、生物药、放射医学、siRNA、细胞与基因治疗等前沿技术，培育本土自主研发能力。
3
神经科学领域战略合作方面，双方将重点围绕神经退行性疾病领域开展合作，特别是在阿尔茨海默病领域，创新疗法和药物可及性仍存在巨大的未满足需求，将共同探索及应对这一重大的全球健康挑战。
王兴利
复星医药联席总裁、创新药事业部首席执行官
“
我们很高兴能与Arcera建立战略合作关系，这是复星医药深化国际合作，开拓全球市场的新里程碑。Arcera是一家实力雄厚的行业领先企业，我们相信，结合复星医药三十多年来在全球研发与产业化领域所积累的系统性能力，将为我们双方的合作注入更强信心。我们期待与Arcera紧密协作，充分发挥各自优势，加速在中东及全球范围内推出创新疗法，让我们的创新成果惠及全球更多患者。
”
Isabel Afonso
Arcera首席执行官
“
今天，意味着我们在阿联酋打造全球化生命科学生态系统的征程中又迈出了关键一步。通过将复星医药成熟的全球化研发能力与Arcera的国际商业化及生产能力相结合，我们将携手打造中阿创新合作典范，加速生物医药技术创新，让前沿疗法惠及更多患者。本次与复星医药的合作是我们首个战略合作项目，将助力阿布扎比成为连接亚洲创新与全球市场的重要桥梁。
”
Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework
- Strategic framework established for regional and global licensing, frontier technology incubation, and strategic collaboration in neurodegenerative diseases
- Joint R&D aligned with China-UAE bilateral partnership and Abu Dhabi''s Healthcare Life Sciences Vision 2030
Abu Dhabi, United Arab Emirates and Shanghai, China, April 28, 2026 – Arcera Life Sciences (“Arcera”), a global life sciences company headquartered in Abu Dhabi, and Shanghai Fosun Pharmaceutical Group Co., Ltd.(“Fosun Pharma”), an innovation-driven global pharmaceutical and healthcare group, today announced the signing of a Memorandum of Understanding (MoU) to establish a long-term strategic collaboration focused on licensing, technology development, neuroscience innovation and value creation in the global life sciences sector.
The agreement was executed by Sunil Bhilotra, Chief Investment Officer of Arcera, and Xingli Wang, Co-President of Fosun Pharma, CEO of Innovative Medicines Division in Shanghai, China. The signing ceremony was witnessed by Qunbin Wang, Co-Chairman of Fosun International; Yuqing Chen, Chairman of Fosun Pharma; Isabel Afonso, Chief Executive Officer of Arcera; and Rafael Ferrer, SVP Corporate Development of Arcera.
Aligned with the Comprehensive Strategic Partnership between the People''s Republic of China and the UAE and Abu Dhabi''s Healthcare Life Sciences Vision 2030 objectives, this MoU creates pathways for innovation and market access in both countries. The collaboration combines Fosun Pharma''s world-class R&D and manufacturing capabilities with Arcera''s international market access and commercial infrastructure, positioning Abu Dhabi as a premier bridge between Chinese biotech innovation and global markets while accelerating patient access to breakthrough therapies across the Middle East and beyond.
As part of the agreement, Fosun Pharma and Arcera will explore collaboration across three key areas:
1
Regional and global licensing of assets:
The collaboration will initially focus on identifying potential licensing opportunities for Fosun Pharma assets in oncology, neuroscience, rare diseases and cardiometabolic disease, including compounds currently in advanced clinical development or commercial stages in China.
2
Frontier technology incubation: Exploration of joint ventures or new entities to localize cutting-edge biotechnology and foster sovereign R&D capabilities in the UAE across small molecules, biologics, radiopharmaceuticals, small interfering RNA therapies, and cell and gene therapies.
3
Strategic collaboration in neuroscience: The neuroscience collaboration will focus particularly on neurodegenerative diseases, including Alzheimer''s disease programs, addressing a critical global health challenge where both innovative therapeutics and regional access remain significant unmet needs.
Isabel Afonso, CEO of Arcera commented:“Today marks another step forward in our journey to build a truly global life sciences ecosystem anchored in the UAE. By combining Fosun Pharma''s proven drug development capabilities with Arcera''s international commercial and manufacturing capabilities, we are creating a model for how China-UAE collaboration can accelerate both biotechnology innovation and patient access to breakthrough therapies. This is our first strategic partnership that will position Abu Dhabi as the bridge between Asian innovation and global markets.”
Xingli Wang, Co-President of Fosun Pharma, CEO of Innovative Medicines Division, said:“We are excited to establish this strategic partnership with Arcera, which marks a pivotal milestone for Fosun Pharma in deepening international collaboration and expanding into global markets. Arcera is a formidable industry player, and we are confident that our systematic capabilities built over more than 30 years in global R&D and manufacturing, will instill greater confidence in our collaboration. We look forward to working closely with Arcera, leveraging our respective strengths to accelerate the delivery of innovative therapies in the Middle East and across the globe, so that our innovative achievements can benefit more patients worldwide.”